Facilitators and barriers to shared decision-making in France in 2021: National survey in cancer
CONCLUSIONS: In this survey, less than half of the patients declared that they have been enrolled in a SDM approach, this rate varying according to the type of solid tumor or hematological malignancy. This study shows that to improve the implementation of SDM in routine clinical practice in cancer, sufficient time and use of decision aids are needed.PMID:37355394 | DOI:10.1016/j.bulcan.2023.04.019 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - June 24, 2023 Category: Cancer & Oncology Authors: L éna Milan Sandra Douc ène Gilbert Lenoir Fadila Farsi Nora Moumjid Fran çois Blot Source Type: research
Diagnosis and management of interstitial lung disease induced by antibody-drug conjugates in breast cancer: A French expert opinion paper
Bull Cancer. 2023 Jun 16:S0007-4551(23)00208-4. doi: 10.1016/j.bulcan.2023.04.013. Online ahead of print.ABSTRACTInterstitial lung disease (ILD) has been reported with many cancer drugs including some recent antibody-drug conjugates (ADCs). The mechanisms of ILD induced by many chemotherapy drugs, other drug classes and ADCs used in cancer, including breast cancer, are not clearly elucidated. In the absence of specific clinical or radiological signs, the diagnosis of drug-induced ILD is often a diagnosis of exclusion. When present, the most frequent symptoms are respiratory signs (cough, dyspnea, chest pain) and general si...
Source: Bulletin du Cancer - June 18, 2023 Category: Cancer & Oncology Authors: Luis Teixeira V éronique Diéras Bruno Crestani Mathieu Lederlin Cristian Villanueva Boris Duchemann Jean-Yves Pierga Jacques Cadranel Source Type: research
Diagnosis and management of interstitial lung disease induced by antibody-drug conjugates in breast cancer: A French expert opinion paper
Bull Cancer. 2023 Jun 16:S0007-4551(23)00208-4. doi: 10.1016/j.bulcan.2023.04.013. Online ahead of print.ABSTRACTInterstitial lung disease (ILD) has been reported with many cancer drugs including some recent antibody-drug conjugates (ADCs). The mechanisms of ILD induced by many chemotherapy drugs, other drug classes and ADCs used in cancer, including breast cancer, are not clearly elucidated. In the absence of specific clinical or radiological signs, the diagnosis of drug-induced ILD is often a diagnosis of exclusion. When present, the most frequent symptoms are respiratory signs (cough, dyspnea, chest pain) and general si...
Source: Bulletin du Cancer - June 18, 2023 Category: Cancer & Oncology Authors: Luis Teixeira V éronique Diéras Bruno Crestani Mathieu Lederlin Cristian Villanueva Boris Duchemann Jean-Yves Pierga Jacques Cadranel Source Type: research
Diagnosis and management of interstitial lung disease induced by antibody-drug conjugates in breast cancer: A French expert opinion paper
Bull Cancer. 2023 Jun 16:S0007-4551(23)00208-4. doi: 10.1016/j.bulcan.2023.04.013. Online ahead of print.ABSTRACTInterstitial lung disease (ILD) has been reported with many cancer drugs including some recent antibody-drug conjugates (ADCs). The mechanisms of ILD induced by many chemotherapy drugs, other drug classes and ADCs used in cancer, including breast cancer, are not clearly elucidated. In the absence of specific clinical or radiological signs, the diagnosis of drug-induced ILD is often a diagnosis of exclusion. When present, the most frequent symptoms are respiratory signs (cough, dyspnea, chest pain) and general si...
Source: Bulletin du Cancer - June 18, 2023 Category: Cancer & Oncology Authors: Luis Teixeira V éronique Diéras Bruno Crestani Mathieu Lederlin Cristian Villanueva Boris Duchemann Jean-Yves Pierga Jacques Cadranel Source Type: research
Diagnosis and management of interstitial lung disease induced by antibody-drug conjugates in breast cancer: A French expert opinion paper
Bull Cancer. 2023 Jun 16:S0007-4551(23)00208-4. doi: 10.1016/j.bulcan.2023.04.013. Online ahead of print.ABSTRACTInterstitial lung disease (ILD) has been reported with many cancer drugs including some recent antibody-drug conjugates (ADCs). The mechanisms of ILD induced by many chemotherapy drugs, other drug classes and ADCs used in cancer, including breast cancer, are not clearly elucidated. In the absence of specific clinical or radiological signs, the diagnosis of drug-induced ILD is often a diagnosis of exclusion. When present, the most frequent symptoms are respiratory signs (cough, dyspnea, chest pain) and general si...
Source: Bulletin du Cancer - June 18, 2023 Category: Cancer & Oncology Authors: Luis Teixeira V éronique Diéras Bruno Crestani Mathieu Lederlin Cristian Villanueva Boris Duchemann Jean-Yves Pierga Jacques Cadranel Source Type: research
Diagnosis and management of interstitial lung disease induced by antibody-drug conjugates in breast cancer: A French expert opinion paper
Bull Cancer. 2023 Jun 16:S0007-4551(23)00208-4. doi: 10.1016/j.bulcan.2023.04.013. Online ahead of print.ABSTRACTInterstitial lung disease (ILD) has been reported with many cancer drugs including some recent antibody-drug conjugates (ADCs). The mechanisms of ILD induced by many chemotherapy drugs, other drug classes and ADCs used in cancer, including breast cancer, are not clearly elucidated. In the absence of specific clinical or radiological signs, the diagnosis of drug-induced ILD is often a diagnosis of exclusion. When present, the most frequent symptoms are respiratory signs (cough, dyspnea, chest pain) and general si...
Source: Bulletin du Cancer - June 18, 2023 Category: Cancer & Oncology Authors: Luis Teixeira V éronique Diéras Bruno Crestani Mathieu Lederlin Cristian Villanueva Boris Duchemann Jean-Yves Pierga Jacques Cadranel Source Type: research
New drug approval: Teclistamab as monotherapy in patients with relapsed or refractory multiple myeloma who received three or more lines of therapy
Bull Cancer. 2023 Jun 7:S0007-4551(23)00090-5. doi: 10.1016/j.bulcan.2023.01.021. Online ahead of print.NO ABSTRACTPMID:37296008 | DOI:10.1016/j.bulcan.2023.01.021 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - June 9, 2023 Category: Cancer & Oncology Authors: Sophie Le Grand Lionel Karlin Source Type: research
New drug approval: Teclistamab as monotherapy in patients with relapsed or refractory multiple myeloma who received three or more lines of therapy
Bull Cancer. 2023 Jun 7:S0007-4551(23)00090-5. doi: 10.1016/j.bulcan.2023.01.021. Online ahead of print.NO ABSTRACTPMID:37296008 | DOI:10.1016/j.bulcan.2023.01.021 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - June 9, 2023 Category: Cancer & Oncology Authors: Sophie Le Grand Lionel Karlin Source Type: research
New drug approval: Teclistamab as monotherapy in patients with relapsed or refractory multiple myeloma who received three or more lines of therapy
Bull Cancer. 2023 Jun 7:S0007-4551(23)00090-5. doi: 10.1016/j.bulcan.2023.01.021. Online ahead of print.NO ABSTRACTPMID:37296008 | DOI:10.1016/j.bulcan.2023.01.021 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - June 9, 2023 Category: Cancer & Oncology Authors: Sophie Le Grand Lionel Karlin Source Type: research
New drug approval: Teclistamab as monotherapy in patients with relapsed or refractory multiple myeloma who received three or more lines of therapy
Bull Cancer. 2023 Jun 7:S0007-4551(23)00090-5. doi: 10.1016/j.bulcan.2023.01.021. Online ahead of print.NO ABSTRACTPMID:37296008 | DOI:10.1016/j.bulcan.2023.01.021 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - June 9, 2023 Category: Cancer & Oncology Authors: Sophie Le Grand Lionel Karlin Source Type: research
New drug approval: Teclistamab as monotherapy in patients with relapsed or refractory multiple myeloma who received three or more lines of therapy
Bull Cancer. 2023 Jun 7:S0007-4551(23)00090-5. doi: 10.1016/j.bulcan.2023.01.021. Online ahead of print.NO ABSTRACTPMID:37296008 | DOI:10.1016/j.bulcan.2023.01.021 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - June 9, 2023 Category: Cancer & Oncology Authors: Sophie Le Grand Lionel Karlin Source Type: research
New drug approval: Teclistamab as monotherapy in patients with relapsed or refractory multiple myeloma who received three or more lines of therapy
Bull Cancer. 2023 Jun 7:S0007-4551(23)00090-5. doi: 10.1016/j.bulcan.2023.01.021. Online ahead of print.NO ABSTRACTPMID:37296008 | DOI:10.1016/j.bulcan.2023.01.021 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - June 9, 2023 Category: Cancer & Oncology Authors: Sophie Le Grand Lionel Karlin Source Type: research
New drug approval: Teclistamab as monotherapy in patients with relapsed or refractory multiple myeloma who received three or more lines of therapy
Bull Cancer. 2023 Jun 7:S0007-4551(23)00090-5. doi: 10.1016/j.bulcan.2023.01.021. Online ahead of print.NO ABSTRACTPMID:37296008 | DOI:10.1016/j.bulcan.2023.01.021 (Source: Bulletin du Cancer)
Source: Bulletin du Cancer - June 9, 2023 Category: Cancer & Oncology Authors: Sophie Le Grand Lionel Karlin Source Type: research
Effectiveness of radiotherapy and targeted radionuclide therapy for melanoma in preclinical mouse models: A combination treatments overview
Bull Cancer. 2023 Jun 3:S0007-4551(23)00216-3. doi: 10.1016/j.bulcan.2023.05.002. Online ahead of print.ABSTRACTCutaneous melanoma is an aggressive and highly metastatic skin cancer. In recent years, immunotherapy and targeted small-molecule inhibitors have improved the overall survival of patients. Unfortunately, most patients in advanced stages of disease exhibit either intrinsically resistant or rapidly acquire resistance to these approved treatments. However, combination treatments have emerged to overcome resistance, and novel treatments based on radiotherapy (RT) and targeted radionuclide therapy (TRT) have been deve...
Source: Bulletin du Cancer - June 5, 2023 Category: Cancer & Oncology Authors: Israel Lara-Vega Maximiliano V M Correa-Lara Armando Vega-L ópez Source Type: research
Effectiveness of radiotherapy and targeted radionuclide therapy for melanoma in preclinical mouse models: A combination treatments overview
Bull Cancer. 2023 Jun 3:S0007-4551(23)00216-3. doi: 10.1016/j.bulcan.2023.05.002. Online ahead of print.ABSTRACTCutaneous melanoma is an aggressive and highly metastatic skin cancer. In recent years, immunotherapy and targeted small-molecule inhibitors have improved the overall survival of patients. Unfortunately, most patients in advanced stages of disease exhibit either intrinsically resistant or rapidly acquire resistance to these approved treatments. However, combination treatments have emerged to overcome resistance, and novel treatments based on radiotherapy (RT) and targeted radionuclide therapy (TRT) have been deve...
Source: Bulletin du Cancer - June 5, 2023 Category: Cancer & Oncology Authors: Israel Lara-Vega Maximiliano V M Correa-Lara Armando Vega-L ópez Source Type: research
